Search results
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 4 days agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 4 days agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie announces LEVEL UP results in atopic dermatitis study By Investing.com
Investing.com· 4 days agoThe study focused on adult and adolescent patients who had an inadequate response to systemic...
Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks· 7 days agoAhead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. Numerous empirical studies consistently demonstrate a strong relationship ...
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
Reuters via Yahoo Finance· 4 days ago(Corrects to remove extraneous text and to add Regeneron ticker symbol) April 25 (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory ...
AbbVie Reports First-Quarter 2024 Financial Results
Valley City Times Record· 3 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 4 days agoThe Zacks Consensus Estimate for Lilly's 2024 EPS has risen from $12.40 per share to $12.52 over the...
High Deep-Remission Rate With Triple Regimen for Relapsed/Refractory CLL
MedPage Today· 6 days agoTime-limited treatment with a three-drug combination for relapsed/refractory chronic lymphocytic...
Takeda Pharmaceutical: A Long-Term Cash Cow
GuruFocus.com via Yahoo Finance· 6 days agoAccording to a study published in Nature, the global prevalence of gastro-oesophageal reflux disease is approximately 14%, highlighting the significant...
Uveitis History Linked to Recurrence After COVID Vaccination
MedPage Today· 5 days agoPeople with a history of uveitis were more likely to experience recurrences of the potentially...
